IL6 and pneumonia: Among 89 elderly patients with severe pneumonia, the SFI treatment group had significantly decreased levels of TNF-α, IL-6, and IL-8 7 days after administration, indicating that SFI effectively reduced inflammatory mediators, thus, playing an active therapeutic effect (Lv et al., 2017).